31 Jul

A Look at Dentsply Sirona’s Expected Bottom Line in Q2 2018

WRITTEN BY Kenneth Smith

Operational performance

Dentsply Sirona’s (XRAY) SG&A (selling, general, and administrative) expenses are expected to increase from $417.6 million in the second quarter of 2017 to $412.91 million in the second quarter. Its total operating expenses are expected to decrease 34.16% from $866.1 million in the second quarter of 2017 to $570.27 million in the second quarter.

A Look at Dentsply Sirona’s Expected Bottom Line in Q2 2018

Bottom line

Dentsply Sirona (XRAY) is expected to report net income of $92.15 million in the second quarter, compared with a net loss of $1.05 billion in the second quarter of 2017. This translates to net income of $0.38 per share in the second quarter, compared with a net loss of $4.58 per share in the second quarter of 2017.

Analysts’ recommendations

Nine of the 16 analysts covering Dentsply Sirona in July gave the stock a “buy” or higher rating. Six analysts gave it a “hold” rating, and one analyst gave Dentsply a “sell” rating. The mean rating for Dentsply is 2.19 with a target price of $58.54.

Analysts gave mean ratings of 2.67, 2.29, 2.07, and 2.55, respectively, to XRAY’s peers, Varian Medical Systems (VAR), Johnson & Johnson (JNJ), Gilead Sciences (GILD), and Bristol-Myers Squibb (BMY). Analysts gave target prices of $122.14, $143.20, $86.00, and $57.56, respectively, to VAR, JNJ, GILD, and BMY.

Price performance

So far in 2018, Dentsply stock has been trending lower. From a high of $68.47 on January 8, Dentsply corrected to $41.64 on June 6. Since then, it’s recovered to its current $47.00 level.

Currently, Dentsply trades at a forward price-to-earnings multiple of 16.91x. Its price-to-sales ratio is 2.68, and its price-to-book ratio is 1.62. Its return on assets stands at 2.88%.

Latest articles

In Q3, billionaire investor Leon Cooperman's top five holdings were Fiserv, Alphabet, United Continental, Chimera Investment, and Cigna.

In 2018, 3,503 metric tons of gold were produced globally, 1.8% higher than in 2017. Let's look at the world's top gold-producing countries.

TJX Companies (TJX) reported better-than-expected earnings results for the third quarter of fiscal 2020, which ended on November 2.

Despite Canada's legalization of cannabis a year ago, a StatCan survey found that 42% of Canadians have obtained their cannabis from illegal sources.

On November 11, the NHS (National Health Service) approved two cannabis-based medicines, Epidyolex and Sativex, for use in the United Kingdom.

Roku (ROKU) stock tanked more than 5% on Tuesday during market hours. The company said it will issue nearly 1 million common shares today.